YI vs. ALVR, BTAI, MIST, SLS, DMAC, ALLK, PMVP, BYSI, PRPH, and SGMO
Should you be buying 111 stock or one of its competitors? The main competitors of 111 include AlloVir (ALVR), BioXcel Therapeutics (BTAI), Milestone Pharmaceuticals (MIST), SELLAS Life Sciences Group (SLS), DiaMedica Therapeutics (DMAC), Allakos (ALLK), PMV Pharmaceuticals (PMVP), BeyondSpring (BYSI), ProPhase Labs (PRPH), and Sangamo Therapeutics (SGMO). These companies are all part of the "medical" sector.
111 (NASDAQ:YI) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.
111 has higher revenue and earnings than AlloVir. 111 is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
AlloVir has a net margin of 0.00% compared to 111's net margin of -2.62%. 111's return on equity of 0.00% beat AlloVir's return on equity.
AlloVir has a consensus target price of $18.50, indicating a potential upside of 2,212.50%. Given AlloVir's higher probable upside, analysts plainly believe AlloVir is more favorable than 111.
111 received 163 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 61.69% of users gave 111 an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
21.3% of 111 shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 43.9% of 111 shares are owned by company insiders. Comparatively, 40.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, AlloVir had 1 more articles in the media than 111. MarketBeat recorded 8 mentions for AlloVir and 7 mentions for 111. 111's average media sentiment score of 0.20 beat AlloVir's score of -0.80 indicating that 111 is being referred to more favorably in the media.
111 has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Summary
111 beats AlloVir on 9 of the 16 factors compared between the two stocks.
Get 111 News Delivered to You Automatically
Sign up to receive the latest news and ratings for YI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
